Breast cancer and the new taxanes: Focus on nab-paclitaxel

Community Oncology

Volumn 5, Issue 7 SUPPL. 8, 2008, Pages 7-13

  Scheff, Ronald J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CAPECITABINE; CREMOPHOR; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; NANOPARTICLE; OSTEONECTIN; PACLITAXEL; POLYGLUTAMIC ACID; POLYSORBATE 80; STEROID; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN BINDING; RASH; REVIEW; RISK FACTOR; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TRANSCYTOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 48249097070     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of Taxol with human serum albumin. Biochim Biophys Acta 2000;1478:61-68.
2. Paál K, Müller J, Hegedûs L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001;268:2187-2191.
3. Trieu V, Frankel T, Labao E, et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs Taxol. Proc Am Assoc Cancer Res 2005;46:5584.
4. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005;72:267-272.
5. Hawkins M, Desai N, Soon-Shiong P, et al. Rationale, preclinical support, and clinical proof-of-concept for formulating water-insoluble therapeutics as albumin-stabilized nanoparticles: experience with paclitaxel. Proc Am Assoc Cancer Res 2005;46:3.
6. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-1324.
7. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
8. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061-2068.
9. Guan Z, Feng F, Li QL, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25(18S):1038.
10. Gradishar W, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25(18S):1032.
11. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 2004;22(14S):510.
12. Roy V, LaPlant BR, Gross GG, et al. NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC). J Clin Oncol 2007;25(18S):1048.
13. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
14. Somer BG, Schwartzberg LS, Arena F, Epperson A, Fu D, Fortner BV. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel [ABX]) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol 2007;25(18S):1053.
15. Trieu V, Ran S, Bivens C, Desai N. Chemoprotection by VEGF: rationale for combination nab-paclitaxel and bevacizumab. J Clin Oncol 2007;25(18S):1064.
16. Conlin AK, Seidman AD, Moynahan ME, et al. Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: an initial interim safety report. J Clin Oncol 2007;25(18S):1104.